新开源(300109) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 307,485,118.87, a decrease of 18.26% year-over-year[4] - Net profit attributable to shareholders was CNY 62,131,375.22, down 36.80% compared to the same period last year[4] - Basic earnings per share decreased by 35.00% to CNY 0.13[4] - Total operating revenue for the current period was ¥951,499,451.66, a decrease of 14.3% compared to ¥1,110,998,865.19 in the previous period[23] - Operating profit decreased to ¥246,285,561.67, down 32.5% from ¥365,444,704.90 in the previous period[23] - The total profit for the current period is ¥247,112,754.41, a decrease of 31.5% compared to ¥361,362,351.81 in the previous period[24] - The net profit attributable to shareholders of the parent company is ¥201,088,081.22, down 35.5% from ¥311,243,169.86 year-on-year[24] - The company reported a net profit margin decline, with net profit for the period not specified but indicated by the decrease in operating profit and revenue[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,242,583,261.89, a decrease of 2.96% from the end of the previous year[4] - Total assets decreased to ¥4,242,583,261.89 from ¥4,372,054,795.55, a decline of 3.0%[21] - Total liabilities decreased significantly to ¥552,113,797.56 from ¥764,369,013.92, a reduction of 27.7%[20] - Non-current assets totaled ¥2,694,635,651.16, down from ¥2,860,302,242.49, reflecting a decrease of 5.8%[20] - The company's equity attributable to shareholders increased to ¥3,722,171,012.11 from ¥3,637,934,717.51, an increase of 2.3%[20] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 213,795,586.24, down 24.58%[4] - The net cash flow from operating activities is ¥213,795,586.24, a decline of 24.5% compared to ¥283,480,027.15 in the previous period[26] - The total cash and cash equivalents at the end of the period is ¥452,253,258.50, compared to ¥258,209,827.62 at the end of the previous period, indicating an increase of 75.2%[27] - The cash inflow from operating activities totaled ¥987,024,485.78, slightly down from ¥1,012,192,179.39 in the previous period[26] - The cash outflow from investing activities was ¥241,453,522.90, compared to ¥296,772,529.36 in the previous period, showing a decrease of 18.7%[26] - The net cash flow from financing activities was -¥303,645,420.70, compared to a positive cash flow of ¥9,457,768.10 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,248[11] - The largest shareholder, Wang Donghu, holds 8.66% of shares, totaling 42,095,222 shares, with 31,571,416 shares pledged[11] - The company plans to distribute a cash dividend of 2.493056 RMB per 10 shares, totaling 121,175,001.25 RMB, based on a total share capital of 486,050,005 shares[16] - The top ten shareholders collectively hold a significant portion of the company's equity, with the largest holding being 8.66%[11] - There are no changes in the status of shares for the top ten shareholders due to margin trading activities[12] - The company has no preferred shareholders or changes in restricted shares during the reporting period[13] Research and Development - R&D expenses increased by 33.76% to CNY 55,383,433.26, reflecting higher investment in innovation[10] - Research and development expenses rose to ¥55,383,433.26 from ¥41,403,619.57, marking an increase of 33.7%[23] - The company’s subsidiary has received approval for clinical trials of a new drug targeting advanced solid tumors[16] Other Information - The company reported a significant increase in long-term borrowings by 656.82% to CNY 156,014,509.38, indicating a shift in financing strategy[10] - The company experienced a 49.33% decline in net profit after deducting non-recurring gains and losses, totaling CNY 52,518,461.73[4] - The company has invested a total of 50 million RMB in Huadao (Shanghai) Biomedical Co., Ltd., acquiring 12.2150% and 0.7168% equity stakes[17] - The company’s board member Zhao Wei is under investigation for alleged insider trading activities[16] - The company has no new strategies or mergers and acquisitions reported in this period[18]